UROLOGIC NEOPLASMS
Clinical trials for UROLOGIC NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new UROLOGIC NEOPLASMS trials appear
Sign up with your email to follow new studies for UROLOGIC NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New immunotherapy combo may save bladders in cancer patients
Disease control OngoingThis phase 2 trial tests two immunotherapy drugs, nivolumab and relatlimab, given before surgery for stage II-IIIa bladder cancer. The goal is to see if the combination can eliminate the tumor, allowing patients to keep their bladder instead of having it removed. About 90 partici…
Matched conditions: UROLOGIC NEOPLASMS
Phase: PHASE2 • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New hope for rare kidney cancer: targeted drug savolitinib faces off against standard therapy
Disease control OngoingThis phase 3 study compares a new drug, savolitinib, to the standard drug sunitinib in 60 people with a specific type of advanced kidney cancer called MET-driven papillary renal cell carcinoma. The goal is to see if savolitinib is better at stopping the cancer from growing and to…
Matched conditions: UROLOGIC NEOPLASMS
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat HER2 cancers
Disease control OngoingThis study tests a two-drug combination (tucatinib and trastuzumab) in people with advanced solid tumors that have HER2 alterations. The goal is to see if the treatment can shrink or control tumors. About 217 participants with various cancers (like lung, uterine, or bile duct) wi…
Matched conditions: UROLOGIC NEOPLASMS
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC